Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evotec invests $18 million in Exscientia

by Ryan Cross
October 9, 2017 | A version of this story appeared in Volume 95, Issue 40

The German contract research firm Evotec is expanding a partnership with the AI-based drug discoverer Exscientia and acquiring an $18 million stake in the company. Evotec’s collaboration with the British firm began 18 months ago to design immuno-oncology drugs that purposefully bind two targets. Evotec CEO Werner Lanthaler liked what he saw. The new deal makes the two firms 50:50 partners on their drug discovery program, Lanthaler says, adding that it is unlikely Evotec would take a compound to the clinic alone.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.